Ingiliz P

9 publications in the catalogue · 2008–2019 · 1 as first author

9 publications

Diseases

  1. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019

    FibroTest NashTest SteatoTest HIV

  2. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017

    FibroTest HCV HIV

  3. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010

    FibroTest Alcohol HBV HCV +3

  4. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009

    FibroTest Alcohol HBV HCV +3

  5. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008

    ActiTest FibroTest HCV

  6. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008

    FibroTest Alcohol HBV HCV +3

  7. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008

    ActiTest FibroTest SteatoTest Alcohol +5

  8. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008

    FibroTest Alcohol HBV HCV +3

  9. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008

    FibroTest Alcohol HBV HCV